These mutated diseases defy the power of antibiotics. Are illnesses really mutating so fast that we can’t stay ahead of them?

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

High Paxlovid costs and prescribing barriers limit access for older adults and high-risk patients, despite continued free ...

UN Women Cameroon supports vulnerable women and survivors of violence in seven refugee camps in three regions ...

May 2025. More for You ...

Antimicrobial-resistant (AMR) “superbugs” contribute to more than 4.5 million deaths globally per year and threaten to make ...

Pfizer's price-to-earnings-to-growth (PEG) ratio, which is based on analysts' five-year earnings growth projections, is a super-low 0.6. I believe Pfizer checks off all the boxes to be a good pick ...

Asked if he expects Pfizer to dominate new prescriptions, Bourla said “correct,” adding that the company will be “super dominant on the current prescriptions.” Alnylam has other ideas. On a conference ...

Pfizer is currently a high-yield quality stock trading at reasonable valuations, indicating a margin of safety that surely curtails investment risks. With the stock market subject to bouts of ...

Some X users were pleased with the Pfizer ad's "wholesome" presentation of the fight toward a cancer cure Others were unsure how to feel about the "effective" approach Pfizer took in its Super ...

After all, the Super Bowl of commercials is the Super Bowl ... A young boy fights cancer — in boxing shorts, natch — in a spot for Pfizer set to L.L. Cool J's 1990 hit "Mama Said Knock ...